Inhibitex, Inc. (NASDAQ: INHX) is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. The Company is developing a portfolio of high-value, differentiated infectious disease therapies. Inhibitex’s pipeline addresses significant viral and bacterial infections, including herpes zoster (shingles), chronic hepatitis C, and S. aureus infections. For further information, visit the Company’s Web site at www.inhibitex.com.

Noble Financial, a research driven, full-service investment banking boutique, is as discriminating with its invitations to institutional investors as it is with the companies invited to present. Rather than just focusing on crowding the conference floor, Noble Financial carefully invites a smaller audience of investors with a large appetite for the companies presenting; quality always trumps quantity. For more information or to view webcasts of today’s presentations, visit www.noblefcm.com.

Let us hear your thoughts below: